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Pain management in  critically ill patients
Abstract 
Pain is a common and distressing symptom in intensive care unit (ICU) 
patients and despite of pain research, guideline development, numerous 
awareness campaigns and intense educational efforts, it remains currently 
under evaluated and undertreated. The pain relief in critically ill patients 
may be difficult to achieve due to complex interplay between mechanisms of 
critical illness, drug interactions, organ dysfunctions and factors involved in 
influencing pain perception. A different medications have been proposed for 
pain control and they have unique considerations when contemplated for 
use in the critically ill patient.
The purpose of this article is to provide an overview of most important 
pharmacologic pain treatment in the critically ill patient.
IntroductIon 
Pain is a common and distressing symptom in intensive care unit (ICU) patients and represents a major clinical, social, and econom-
ic problem. It has been reported that almost 80% of patients experience 
different intensities of pain during their intensive care unit stay and 
identify it as one of the greatest sources of stress (1, 2). 
Such pain is problematic because produces adverse psychological and 
physiological response that includes increased heart rate, blood pressure, 
respiratory rate, neuroendocrine secretion and psychological distress. 
Failure to relieve pain produces a prolonged stress state, which can result 
in harmful multisystem effects and can therefore impair a patients re-
covery and discharge (3). The primary goal of acute pain management 
in ICU patients are pain control and attenuation of the negative physi-
ologic and psychological consequences of unrelieved pain. Although, a 
number of recent surveys, reported that enhanced pain management 
was associated with improved patient outcome in the ICU (4, 5) and 
despite of pain research, guideline development, numerous awareness 
campaigns and intense educational efforts, pain remains currently under 
evaluated and undertreated in patients who are critically ill (6). There-
fore, the importance of quality pain management in the ICU is inher-
ently compelling and highly challenging. 
Etiology and pain assessment in Icu patients 
Although, adequate pain control is a basic human right (6), a number 
of factors complicate the management of pain in the critically ill patient. 
In particular, critically ill patients may experience pain due to their 
underlying disease or surgery, but also it may be result of various and 
painful medical procedures (procedural pain) such as inserting urinary 
catheter, nasogastric tube, chest tubes, tracheal suctioning, invasive 
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lines, (arterial and central venous catheter) suture remov-
al and routine nursing care. Nursing care procedures such 
as bathing, massage of back and pressure points, sheets 
change and repositioning are the most common painful 
procedures in ICU patients (7) Vazquez M et al. (8) ana-
lyzing pain intensity during 330 turnings in 96 medical-
surgical patients and reported significantly increased pain 
score between rest and turning. The bolus of analgesic was 
used in less than 15% of the turnings. Further, although 
some ICU patients may be able to communicate, many 
critically ill patient with cognitive or communication 
problems due to stroke or brain injury, dementia, confu-
sion, mechanical ventilation and concomitant use of 
sedatives, may have difficulty in reporting pain. Presence 
of the some causes mentioned above increases the likeli-
hood for poor pain management, and worsens a patient’s 
experience of pain. The first step in providing adequate 
pain relief for ICU patients is appropriate assessment. 
Pain should be assessed by self-reporting scales in patients 
able to communicate, or by behavioral pain scores in pa-
tients unable to communicate. Even though various self-
report pain scales and behavioral pain scales specifically 
developed for use in critically ill adults are available, these 
are not always routinely used in the ICU. Patients’self-
reporting of their pain is the gold standard of pain assess-
ment and provides the most valid measurement of pain 
(9).  The most widely used pain intensity scales are the 
Numeric Rating Scale (NRS) and Visual Analogue Scale 
(VAS) while Behavioral Pain Scale (BPS) is considered to 
be an alternative tool for assessing pain in critically ill, 
sedated, and mechanically ventilated patients. The BPS 
assesses pain through evaluation of facial expression, up-
per limb movements, and compliance with mechanical 
ventilation. A similar behavioral scale called the Critical-
Care Pain Observation Tool (CPOT) may also be used.
route of administration
The route of medication administration is an impor-
tant consideration for the pharmacologic management of 
pain in the ICU setting. Intravenous administration is 
more commonly the route of choice in critically ill pa-
tients because of altered GI tract function that could lead 
to unpredictable absorption of medication.
The choice of intermittent vs. continuous infusion IV 
administration depends on factors such as the frequency 
and severity of pain, and the pharmacokinetics of the pain 
medication. The administration in bolus is associated 
with the variation in the peak plasma concentration, since 
the infusion maintains a more stable concentration, but 
can lead to accumulation of medication especially in pa-
tients with renal or liver failure.
Patient-controlled analgesia (PCA) is an effective met-
hod for administering analgesic medication and gives 
patients a sense of control over their pain, expecialiy in 
postoperative settings. Patients can determine when and 
how much medication they receive, regardless of analge-
sic technique. However, this technique requires fully con-
scious and orientated patients which make use of PCA 
limited in ICU patients. 
Intravenous administration is generally preferred over 
subcutaneous or intramuscular routes given potentially 
inadequate absorption due to regional hypoperfusion 
(e.g., shock, subcutaneous edema). Regional or neuraxial 
(spinal or epidural) modalities may also be used in ICU 
following selected patients and selected surgical proce-
dures. Epidural analgesia (EA) is probably the most often 
used regional anaesthetic technique in the ICU. EA 
should be proposed in critically ill patients, such as post-
operative after thoracic, abdominal surgery, major vascu-
lar surgery and orthopedic surgery or trauma patients, 
typically.
The major disadvantages of epidural analgesia are the 
rare but catastrophic complications such as infection, epi-
dural hematoma formation and nerve damage, which can 
occurred in ICU patients who have a high risk of develop-
ing these complications (10). 
Pharmacotherapy 
In January 2013, The Society of Critical Care Medi-
cine (SCCM) published the Clinical Practice Guidelines 
for the Management of Pain, Agitation, and Delirium in 
Adult Patients in the Intensive Care Unit (11).  Table 1. 
shows the commonly used pain management drugs and 
recommended doses. There are no data to support the 
preference of analgesic over the other. 
opioids 
Opioids are the primary medications for managing 
pain in critically ill patients because of potency, concom-
itant mild sedative and anxiolytic properties, and their 
ability to be administered by multiple routes. Recom-
mended opioids include fentanyl, remifentanil, morphine, 
and hydromorphone. The choice of opioid and the dosing 
regimen should be individualized based on drug’s po-
tency, pharmacokinetics and pharmacodynamic profiles, 
side effect profile,  patient comorbidities, and function of 
specific organ systems, in particular the liver and kidneys. 
Morphine sulfate is the most frequently used opioid in 
the ICU and has been traditionally a first-line opioid for 
the treatment of severe pain. Morphine has a half-life of 
1.5 to 2h after intravenous administration in normal sub-
jects, but in ICU patient, distribution volume and protein 
binding may be abnormal. Therefore, the patients can 
respond very differently to morphine doses in terms of the 
analgesic effect but also in terms of the side effects. Al-
though, morphine, such as all opioids, may lead to respi-
ratory depression, it is noteworthy to point out that the 
morphine-6-glucuronide metabolite is more potent than 
morphine itself, and that accumulation can occur, espe-
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cially in patients with renal impairment. Therefore, mor-
phine use should be avoided for patients with known renal 
insufficiency or failure. Side effects include histamine re-
lease, sedation, nausea, ileus, constipation, and spasm of 
the sphincter of Oddi. Morphine sulfate should be ad-
ministered intravenously and titrated to effect. The load-
ing dose of 0.05 mg/kg (2–5 mg) should be given over 5 
to 15 min. In most patients, the average maintenance dose 
is 4 to 6 mg/h and should be administered at the dosing 
interval of 1–2 hrs. Continuous IV morphine can be ad-
ministered with an initial 2–5 mg bolus dose followed by 
1 mg/h.
Fentanyl is synthetic opioid roughly 100 times the po-
tency of morphine, which does not cause histamine re-
lease and was preferred analgesic agent for critically ill 
patients with hemodynamic instability. It efficacy is due 
to its lipid solubility (600 times more lipid soluble than 
morphine), so if used > 4 hrs fentanyl must be used in the 
lowest tolerated dose to prevent prolonged effects. With 
prolonged infusion, the half-life increases dramatically 
from 30 – 60 minutes to 9–16 h and care must be taken 
to adjust infusion rate with time.
Fentanyl causes only minor hemodynamic changes 
and does not affect cardiac inotropy. The dose range for 
fentanyl infusions is variable and some patients may re-
quire higher doses. Bolus dose of 25–100 µg, with subse-
quent doses of 0.25–0.5 µg/kg every 15–30 minutes 
might be a good first alternative to morphine in treating 
acute painful conditions. Alternatively, a bolus dose of 
1–2 mcg/kg (25–100 mcg) may be administered followed 
by initiation of the continuous infusion. Most patients 
will be adequately treated with 1 to 2 µg/kg/hr (25–200 
µg/h infusion).
Remifentanil is a fast-acting drug and presents an 
equally fast recovery (11). It is 150 –200 times more potent 
than morphine. Its metabolism does not depend on the 
liver. Analgesia-based sedation with remifentanil is a use-
ful option for mechanically ventilated patients and it can 
be used in patients that need frequent neurological assess-
ment. Studies have shown a shorter duration of mechan-
ical ventilation and quicker ICU discharge with remifen-
tanil compared with other opioids (12, 13). It offers 
precise control of analgesia for painful procedures in ICU 
patients and has a highly predictable onset and offset, 
with a stable context sensitive half-time (3–10 min). No 
need for initial dose adjustment is required for patients 
with impaired renal and hepatic function. Therefore, 
analgesia-based sedation with remifentanil has been in-
troduced as an option in ICU patients. Remifentanil can 
be administrated in higher doses than are normally used 
with other opioids without concerns about accumulation 
and the possibility of unpredictable and/or delayed recov-
ery. Most ICU patients can be managed without bolus 
doses; if required, a bolus of 0.5–1 µg/kg is usually suf-
ficient. It is recommended that remifentanil infusions 
should be started at 6–9 µg/kg/h and than titrated in the 
range dose 0.5–15 µg/kg/h. Some authors recommended 
dose to 60 µg/kg/h (14). Even under these controlled con-
ditions, this practice has not found widespread use be-
cause of the associated incidence of hypotension and bra-
dycardia. 
Hydromorphone is a semisynthetic opioid agonist that, 
like fentanyl, has a more rapid onset of analgesia (within 
30 minutes) and a short half-life (2–4 hours). While the 
duration of action is similar to morphine, it does not 
stimulate histamine release. Hydromorphone is primar-
ily metabolized in the liver to an active metabolite – hi-
dromorphone-3-glucuronide, but it is not clinically sig-
nificant. Hydromorphone is potent respiratory depressant 
and may accumulate in patients with renal failure, result-
ing in neuroexcitation and cognitive impairment. Dosing 
begins at 0.2 to 0.6 mg and titrated by 0.5 mg increments. 
Most patients requiring 1 to 2 mg every 1 to 2 hrs. In 
addition, if given as an intravenous continuous infusion 
the dose should be 0,5 –3 mg/h. 
Tramadol is a centrally acting opioid-like drug, and 
acts by binding to the µ opiate receptor where it is a pure 
agonist like morphine and inhibits adrenaline and sero-
tonin re–uptake. It is used to treat moderate to severe 
pain. The most common adverse effect is typical to other 
opioids and includes nausea, vomiting, dizziness drowsi-
ness, dry mouth and headache. However, tramadol pro-
duces less respiratory and cardiovascular depression than 
morphine, and euphoria and constipation are also less 
common.
Recommended dosage of 100 mg can be administered 
as an initial bolus. During the 90 minutes following the 
initial bolus further doses of 50 mg may be given every 
30 minutes, up to a total dose of 250 mg including the 
initial bolus. Subsequent doses should be 50 mg or 100 
mg 4 to 6 hourly up to a total daily dose of 400 mg.
non-opioid analgesics 
Non-opioid analgesics are indicated for use in manage-
ment of mild to moderate pain and moderate to severe 
pain with adjunctive opioid analgesics. Potential advan-
tages of multimodal analgesia, that involves combination 
of analgesics with different mechanisms of action, include 
improved analgesia, effective analgesia with lower opioid 
doses, and decreased risk of opioid-related adverse effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have 
opioid sparing effect but this has not been sufficiently 
investigated in ICU patients. Although the use of NSAIDs 
is still contraversial, they may be used as adjuncts to opi-
oid therapy. The most common side effect include gastro-
intestinal bleeding, renal dysfunction and inhibition of 
platelet function.
All parenteral NSAIDs should be avoided in patients 
with preexisting renal insufficiency, asthma, hypoperfu-
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sion, advanced age, concomitant use of steroids and anti-
coagulants, situations that are frequently observed in ICU 
patients (15). Treatment should be limited to the mini-
mum dosage for the shortest possible time, not to exceed 
five days.
Acetaminophen (paracetamol) was approved for intra-
venous use in 2010 and is commonly administered for the 
short-term treatment of mild to moderate pain and febrile 
critically ill patients with infection. It differs from the 
available opioids and NSAIDs, since paracetamol does 
not increase incidence of nausea, vomiting, and respira-
tory depression that can occur with opioids, or the plate-
let dysfunction, gastritis, and renal toxicity that are as-
sociated with NSAIDs. Although, represents a relatively 
good safety profile, there is limited information regarding 
IV use in critically ill patients. Research to date has des-
cribed that paracetamol can cause transient abnormaliti-
es of liver function and may cause hypotension in criti-
cally ill patients (16). Acute liver failure is the most 
serious potential complication of the use of paracetamol. 
The key criteria for assessing potential hepatotoxicity with 
conventional doses of paracetamol may include hypoxic 
injury, altered pharmacokinetics, relative over-dosage, 
muscle glutathione depletion, malnutrition, dehydration, 
older age and alcoholism which is often seen in critically 
ill patients. The British National Formulary (BNF) sug-
gests to administer a maximum daily infusion dose of 3 g 
in adults in these patient groups (17).
Randomised, placebo-controlled trial that investiga-
ting the safety and efficacy of paracetamol in febrile ICU 
patients with known or suspected infection is currently 
underway study (the HEAT -Permissive HyperthErmiA 
Through Avoidance of Paracetamol in Known or Suspec-
ted Infection in the Intensive Care Unit) (18). The results 
of this trial are expected to publish in early 2015 and 
should provide essential information on efficacy and 
safety of paracetamol in febrile critically ill patients. The 
recommended dose for IV acetaminophen is 1 g every 6 h 
with a maximum allowable dose of 4 g/daily.
Lidocaine is commonly used for regional anesthesia 
and nerve blocks, however, recent clinical studies demon-
strated that intravenous perioperative administration of 
lidocaine can lead to better postoperative analgesia, re-
duced opioid consumption, improved intestinal motility 
and decrease hospital length of stay (19, 20). Although, 
the analgesic effect depend on dose, there is considerable 
individual variability in pharmacokinetic response to li-
docaine infusions. Serum steady state is achieved fo-
llowing a bolus of 1.5–2.0 mg/kg of lidocaine and infu-
sion rates of 0.9–3.6 mg/kg/h. These doses generally result 
in plasma levels of 1.3–3.7 µg/ml, which provide a small 
Table 1





Suggested Dosage Comments 
Morphine 2-4 h 30 min 2-5 mg bolus 
1-10 mg/h infusion
Avoid in hemodynamically unstable patients. Active 
metabolite accumulates in renal dysfunction. May 
cause itching due to histamine release.
Fentanyl 2-5 h 4 min 25-100 µg bolus 
25-200 µg/h infusion
Fastest onset and shortest duration. Accumulation 
with hepatic impairment.  Muscle rigidity.
Remifentanil 3-10 min 1-3 min 0.5-1 mcg/kg IV bolus 
0.5-15 µg/kg/h infusion
No accumulation in hepatic/renal failure. Use IBW if 
body weight >130% IBW
Hydro-
morphone
2-4 h 20 min 0.5-2 mg bolus and 0.2 to  
0.6 mg every 1-2 h intermittent 
0.5-3 mg/h infusion
Therapeutic option in patients tolerant to morphine/
fentanyl. Accumulation with hepatic/renal impairment 
5-10x more potent than morphine.
Tramadol 5-6 h 45 min 100 mg bolus and 50 mg every 
30 min up to 250 mg including 
the initial bolus. 
total daily dose of 400 mg.
The elimination of tramadol may be prolonged in 
hepatic/renal impairment 
Contraindicated in patients on MAOI or epilepsy.
Acetamino-
phen
2-3 h 15 min 1 g every 6 h May cause hypotension when given by infusion and 
may cause liver and kidney damage, when taken at 
higher than recommended doses (overdose).
Lidocaine 1,5-2 h 45-90 s 100 mg or 1.5–2 mg/kg at least 
half an hour before surgical  
incision, followed by an 
infusion of 1.33–3 mg/kg/h 
intraoperatively
Avoid in patients with arrhythmias, heart failure,  
coronary artery disease, Adams-Stokes, or heart blocks. 
Caution should be taken in patients with hepatic 
or renal failure, sinus bradycardia and incomplete 
branch block.
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marigin of safety. Large doses have better analgesic effect 
but induce systemic lidocaine’s toxicity. Lidocaine induces 
analgesia when serum ranges are kept at 1–5 µg/m. Al-
though the half-life of the drug is only 120 minutes, the 
analgesia provided by systemic lidocaine is prolonged, 
over days or even weeks. With regard to analgesia, it has 
been reported that intravenous lidocaine produces three 
different pain relief stages: the first is during infusion and 
30 to 60 minutes after its end; the second is a transient 
stage approximately 6h after infusion; and the third stage 
appears 24 to 48h after infusion and continues for 21 to 
47 days (21). Intravenous lidocaine should not be used in 
patients with arrhythmias, heart failure, coronary artery 
disease, Adams-Stokes, or heart blocks. Caution should 
be taken also when using lidocaine in patients with he-
patic or renal failure, sinus bradycardia, and incomplete 
branch block since possible accumulation of lidocaine or 
its metabolites may lead to toxic phenomena.
Although there is no clear consensus on the dosage 
regimen, many studies have used a bolus dose of 100 mg 
or 1.5 mg/kg at least half an hour before surgical incision, 
followed by an infusion of 1.33–3 mg/kg/h intraopera-
tively and continued after operation variably up to 24 h. 
The application of continuous lidocaine has not been 
documented in the ICU in controlled studies and more 
study is needed to confirm beneficial effects of lidocaine 
in critically ill patients.
regional anesthesia and analgesia
Regional anesthesia and analgesia although, not com-
monly used as a primary modality for analgesia in criti-
cally ill patients, can help to improve respiratory and 
bowel function, mental status and patient comfort second-
ary to its opioid-sparing effects. It minimizes patient dis-
comfort and reduces the physiological and psychological 
stress, as in non-critical patients.  Limitations for the use 
of regional anesthetic techniques are mainly associated 
with bleeding risks, coagulation disorders, hemodynamic 
disturbances and difficulties in neurologic assessment. The 
use of regional analgesia in the ICU settings should evalu-
ate the risk and benefits due to limited cooperation of the 
patient, and the indication for it use should be carefully 
assessed regarding to patients clinical condition. 
As mentioned above, epidural analgesia is probably the 
regional anaesthetic technique most often used in the 
ICU, but nerve blocks and other sophisticated techniques 
started in the operating room may also be used for pain 
relief in critically ill patients and should not be discontin-
ued when the patient is transferred to ICU. 
conclusIon
Pain management is an essential component of quality 
care delivery for the critically ill patient. The patients in 
ICU often suffer from undertreated and unrecognized 
pain, with potentially serious physical and psychological 
effects. The availability of a wide range of treatment op-
tions together with the recognized importance of adequ-
ate management enables better understand, evaluate and 
manage pain in the critically ill patient. It’s therefore im-
portant for clinicians to recognize a patient’s pain profile 
and rational choice of pain medication should be based 
upon individual needs and desired effect of analgesic. Ef-
fective pain management is a moral imperative and pro-
fessional responsibility for both doctors and nurses.
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